Dave Ricks, the CEO of Eli Lilly, told analysts this week that global use of weight-loss drugs will rise to 30 million patients by 2026. His company is celebrating the launch of Foundayo, a once-daily pill that promises a chemical shortcut to health. More than 20,000 people have already started taking it. While the medical community praises these breakthroughs, we must look at the moral cost of a society that treats its own metabolism as a subscription service.

The U.S. is on pace to spend more than $1 trillion on prescription drugs this year, according to USA Today. GLP-1 drugs like Zepbound and Wegovy are leading the way. The FDA is now proposing restrictions on compounded versions of these drugs, a move that helped Eli Lilly and Novo Nordisk stocks surge. By limiting the ability of local pharmacies to create affordable alternatives, the state is effectively granting a monopoly to the giants of industry.

Health should not be a luxury reserved for those who can pay the highest premium. We are creating a metabolic divide, where the wealthy buy their discipline in a bottle while the poor are left with the consequences of a broken food system. Mr. Ricks has noted that price cuts have increased sales, but he continues to push for broader insurance coverage to fuel the corporate bottom line.

We have forgotten the old virtues of temperance and physical labor. Instead of mending our tables and our habits, we look to the laboratory for a miracle. According to Seeking Alpha, the pharmaceutical giants are dominating a "booming" market. But a boom for the boardroom is often a bust for the national character. We must encourage a culture that prizes self-control over chemical dependence, and a market that serves the person, not the shareholder.